How does Biogen Chief Medical Officer Al Sandrock feel after the curtain was lifted on clinical trial data of the experimental Alzheimer’s drug his company is developing with Japanese drugmaker Eisai?
GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and profits equally, and Glaxo will a
It might seem an odd, even brusque question, especially when asked to the CEO of a major pharmaceutical company by a recently hired employee. But it’s how Hal Barron, the new chief scientific officer GlaxoSmithKline,
Swiss drugmaker Novartis has announced that it will shelve price increases for medicines in the US after criticism of the sector from President Donald Trump over rising costs. “We have voluntarily pulled
Microsoft cofounder Bill Gates revealed more of his plan to invest in Alzheimer's disease research on Tuesday. He along with fellow billionaire Leonard Lauder, the Dolby family, the Charles and Helen Foundation
WASHINGTON/NEW YORK (Reuters) - Pfizer Inc (PFE.N) said on Tuesday it was deferring drug price increases for no more than six months after the company’s chief executive officer had an extensive conversation
A complicated new clinical trial could give some hope to Alzheimer's patients and investors in drug companies. But there are lots of devilish details. Drugmakers Biogen and Eisai said the top dose of experimental